Please use this identifier to cite or link to this item:
http://localhost:8080/xmlui/handle/123456789/7842
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Fakih, Taufik Muhammad | - |
dc.contributor.author | Ramadhan, Dwi Syah Fitra | - |
dc.contributor.author | Arfan | - |
dc.date.accessioned | 2024-11-12T02:20:01Z | - |
dc.date.available | 2024-11-12T02:20:01Z | - |
dc.date.issued | 2022-11 | - |
dc.identifier.issn | 2088 4559 | - |
dc.identifier.uri | http://localhost:8080/xmlui/handle/123456789/7842 | - |
dc.description.abstract | Coronavirus 19 (COVID-19) is still a global health issue to date, SARS-CoV-2 is a novel coronavirus that is responsible for this sickness. The receptor-binding domain of the SARS-CoV-2 virus associates with angiotensin-converting enzyme 2 (ACE-2) and allows the virus to enter human cells. Natural peptides such alpha-defensin are thought to attach to the SARS-CoV-2 RBD and prohibit it from engaging with ACE-2. Molecular dynamics simulations using a computational approach are utilized to understand the stability of six alpha-defensin macromolecules using the Gromacs 2016 software. The trajectories formed are then analyzed using VMD 1.9.4 and BIOVIA Discovery Studio 2020 software. Finally, the free energy is estimated using the MM/PBSA method. The alpha-defensins 2 macromolecules were found to have the best stability based on numerous study results (trajectory visualization, RMSD, RMSF, and free energy calculations). As a result, these macromolecules could be used to build new antiviral treatments for COVID-19 infectious disease candidates | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | Pharmaciana | en_US |
dc.subject | COVID-19 | en_US |
dc.subject | infectious disease | en_US |
dc.subject | SARS-CoV-2 RBD | en_US |
dc.subject | alpha-defensin | en_US |
dc.subject | molecular dynamics | en_US |
dc.subject | computational approach | en_US |
dc.title | Comparative analysis of the stability features of human alpha-defensins as candidates for the future COVID-19 therapy through molecular dynamics | en_US |
dc.type | Article | en_US |
Appears in Collections: | VOL 12 NO 3 2022 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
283-291.pdf | 415.85 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.